ReviewClinical pharmacokinetics2026
Guidance for External Evaluation and Selection of Population Pharmacokinetic Models for Precision Dosing.
Review in Clinical pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Development and evaluation of machine learning-based prediction-modelling for initial vancomycin serum concentrations in septic ICU patients using clinical health record data.Intensive care medicine experimental · 2026Article
- Predictive accuracy of population meropenem models in critically ill pneumonia patients.Antimicrobial agents and chemotherapy · 2026Article
- Unlocking the Potential of Population Pharmacokinetic Models of Adalimumab in Patients with Crohn's Disease.Pharmaceutics · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Model-informed precision dosing relies on population pharmacokinetic models to personalize drug therapy and improve clinical outcomes. While hundreds of models are published, only a small fraction are externally evaluated and even fewer are applied in practice. This gap reflects a lack of clear standardized guidance on how to identify, assess, and implement published models in new clinical settings. This guidance provides a structured step-by-step framework for the external evaluation and selection of published population pharmacokinetic models to support their use in model-informed precision dosing. It outlines key considerations for defining the model's intended use, assessing the characteristics of the available dataset, screening for suitable candidate models, and applying prediction- and simulation-based diagnostics. By addressing methodological and practical challenges, this framework supports more reproduceable use of published models in real-world settings to help bridge the gap between model development and clinical application.
Indexed as
Identifiers
41343019What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.